iPLEDGE and Its Implementation in Dermatology Practices
Gary J. Rosenmeier, MD; Helen M. Torok, MD
Isotretinoin is one option in a dermatologist’s armamentarium for the treatment of acne; however, it is highly teratogenic, and fetal exposure to isotretinoin can cause severe complications. iPLEDGE is a computer-based risk management program designed to help eliminate fetal exposure to isotretinoin by mandating how all isotretinoin products are prescribed and dispensed. Optimal success of the iPLEDGE program requires physician prescribers along with their office staff and patients to perform specific responsibilities to ensure that patients do not start isotretinoin therapy while pregnant or become pregnant during treatment. We discuss how to successfully implement the iPLEDGE program in dermatology practices.